AAP
SMMT icon

Arax Advisory Partners’s Summit Therapeutics SMMT Stock Holding History

Arax Advisory Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
24,044
+23,939
+22,799% +$425K ﹤0.01% 1876
2026
Q1 		$1.98K Buy
105
+11
+12% +$178 ﹤0.01% 3107
2025
Q4 		$1.64K Sell
94
-12
-11% -$226 ﹤0.01% 3331
2025
Q3 		$2.19K Buy
+106
New +$2.57K ﹤0.01% 3097
2025
Q1 		– Sell
-797
Closed -$14.2K – 3013
2024
Q4 		$14.2K Sell
797
-222
-22% -$4.3K ﹤0.01% 1356
2024
Q3 		$22.3K Hold
1,019
– – ﹤0.01% 1039
2024
Q2 		$7.95K Buy
+1,019
New +$5.5K ﹤0.01% 1380

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Arax Advisory Partners's SMMT Position: Q2 2026 in Review

Arax Advisory Partners increased its Summit Therapeutics (SMMT) stake by 22,799% in Q2 2026, buying an estimated $425K and bringing the position to 24,044 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Arax Advisory Partners first reported a position in SMMT in Q2 2024 and has held it in 7 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Arax Advisory Partners held 24,044 shares of Summit Therapeutics worth $350K as of Q2 2026.
  • Arax Advisory Partners bought 23,939 Summit Therapeutics shares in Q2 2026, an estimated $425K.
  • Summit Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1876 holding.
  • Arax Advisory Partners first reported a position in Summit Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.